ADIOSURGERY is commonly used to treat VSs (acoustic neuromas). These common tumors (representing approximately 10% of all primary brain tumors) are benign proliferations of Schwann cells arising from the myelin sheath of the vestibular branch of the eighth cranial nerve. Although their histological characteristics are benign and their behavior is noninvasive, VSs pose a problem because of their proximity to the brainstem and multiple cranial nerves.
Predictably, many of the complications resulting from both microsurgical and radiosurgical treatment of these tumors arise from injury to the nearby brainstem and cranial nerves.
The most frequently observed complications of VS radiosurgery are delayed facial and/or trigeminal neuropathies, the incidence of which has declined dramatically during recent years at our institution. In the present study we sought to identify factors that may be manipulated to reduce the incidence of postradiosurgical cranial neuropathies, while preserving high tumor control rates.
Clinical Material and Methods

Patient Population
During the interval from July 1988 to June 1998, 149 patients were treated with radiosurgery for VS at the University of Florida. The average patient age at treatment was 63.5 years (range 10-88 years). Seventy patients (47%) were male and 79 (53%) were female. The following symptoms were noted on initial presentation for this group: hearing loss (94%), dysequilibrium (30%), facial weakness (18%), facial numbness (15%), dizziness/vertigo (13%), tinnitus (9%), hydrocephalus (5%), and headache (3%). Eight patients (5.4%) harbored bilateral tumors associated with neurofibromatosis and 42 (28%) had undergone previous resection of their tumor. The indications listed in this population for radiosurgery were as follows: age older than 60 years (55%), failed prior surgery (28%), patient preference (14%), and medical infirmity precluding the use of a general anesthetic (3%).
Radiosurgical Treatments
The average tumor volume treated was 4.8 cm 3 (equivalent in volume to a 21-mm-diameter sphere), with a range from 0.3 to 22 cm 3 . Prescription doses to the tumor margin ranged from 10 to 22.5 Gy, including only doses at 2.5-Gy increments (that is, 10, 12.5, 15, 17.5 Gy, and so forth). A mean prescription dose of 14 Gy was delivered, most commonly to the 70% or 80% isodose line. An average of two isocenters (range one-11 isocenters) was used over the entire series, but the number of isocenters we used increased over time, along with the sophistication of dose planning and a trend toward more tightly conformal radiation delivery.
Volumetric Analysis
Using locally developed software and an extensive computerized radiosurgery archive, one neurosurgeon (K.D.F.) outlined the contours of all treated tumors and the pontine segment of each patient's brainstem in 1-mm slices on the original targeting images. The tumor and brainstem volumes thus derived were coupled with the original radiosurgical dosimetry plans to generate pertinent dosevolume histograms for each treatment. Measurements of various tumor dimensions were obtained to estimate the length of the cranial nerve that was irradiated, as in a previous study conducted by another radiosurgery group. 16 Specifically, the pons-petrous tumor diameter was used as an approximation of the length of the trigeminal nerve included in the irradiated field and the pons-petrous diameter plus the length of the intracanalicular tumor component was used to estimate the length of the facial nerve that was irradiated. As in the aforementioned paper, three measures of the diameter of the cerebellopontine angle tumor component were obtained, as were the length and average width of the intracanalicular component. The distance between the tumor and the brainstem was also measured to evaluate the possible importance of this relationship in the incidence of complications.
Follow-Up Review
Clinical and radiological patient follow-up data were obtained from a prospectively maintained, computerized database. For the purposes of this analysis, any new facial or trigeminal neuropathy of any severity or any exacerbation of a previously existing neuropathy was considered a radiation-induced complication. Auditory function was not systematically assessed. The median interval between radiosurgical treatment and onset of symptoms of cranial neuropathy in patients in whom such complications developed was 9 months (range 4-13 months). The complications analysis included 139 (93%) of the 149 patients treated. The remaining 10 patients were eliminated from the analysis because of inadequate follow-up data. Of these, four patients were lost to follow up, four died of intercurrent disease, and two underwent resection for tumor growth and were excluded from the complications portion of this analysis. The median duration of clinical follow up for all patients who were included was 36 months (range 18-94 months). Given that all patients spent a minimum of 18 months in follow-up review, and all cranial neuropathies occurred before 13 months posttreatment, the duration of follow up should have been adequate to ensure that all potential cranial neuropathies in this group were detected.
Duration of radiological follow up was used in the analysis of tumor growth. This sometimes differed from the duration of clinical follow up because imaging studies were not always available for patients whose clinical status was known. Determinations of radiological tumor status (regression, stasis, or growth) were made through a side-by-side comparison of follow-up and pretreatment imaging studies that were conducted by a single neurosurgeon (W.A.F.). The tumor control analysis included 133 (89%) of the 149 patients. Sixteen patients were excluded because no follow-up imaging was available in these cases. The median duration of radiological follow up was 34 months (range 6-94 months). The average posttreatment interval to detection of tumor growth was 25 months (range 7-51 months). Because some tumors displayed enlargement as early as 7 months following radiosurgery, all patients in whom any posttreatment images were available were included in the analysis. This avoided the artificial elimination of patients with demonstrated tumor growth on the basis of a short follow-up duration.
Statistical Analysis
Data used in the analysis consisted of postradiosurgery event times for the occurrence of trigeminal (fifth cranial nerve) and/or facial (seventh cranial nerve) palsy (149 patients), postradiosurgery event times for the occurrence of tumor growth (133 patients), and associated demographic and baseline characteristics and surgical treatment parameters. Four outcome variables were defined and each was analyzed separately: time to occurrence of fifth nerve palsy (13 events observed), time to occurrence of seventh nerve palsy (16 events observed), time to earliest occurrence of either fifth or seventh nerve palsy (20 events observed), and time to occurrence of tumor growth (10 events observed).
Cox proportional hazards regression 10 was used to analyze univariate associations between potential risk factors of interest and each of the outcome variables and to estimate relative risks and corresponding 95% CIs for each risk factor. The score test was used to evaluate the statistical significance of each risk factor. The time of the most recent clinic visit or radiological assessment was used as the right-censored event time for patients who did not experience a particular adverse event by the time of the analysis. Risk factors that could be reasonably viewed as continuous numeric variables were analyzed in both their continuous form (relative risk interpreted as the factor change in risk per unit increase in the risk factor) and as binary risk factors with strata defined by a cutpoint (relative risk interpreted as the factor change in risk in one stratum relative to the other stratum). When possible, each observed value of a continuous risk factor was evaluated as a cutpoint defining a binary risk factor, which was then analyzed by Cox regression. The cutpoint yielding the largest score test statistic and reasonable relative risk estimate was used to define a "best" binary form of the continuous risk factor. Multiple Cox regression was used to identify limited combinations of predictor variables and corresponding interactions that simultaneously were significantly associated with each of the various outcome variables. All two-predictor models plus interaction were evaluated first and then the best two-predictor models yielding the highest score test statistics and reasonable relative risk estimates were subjected to further analysis to determine if additional predictors could significantly account for additional variation in risk. As part of the modelfitting process, delta-beta values were examined to identify influential observations, log(Ϫlog) incidence plots and significance testing of interactions between risk factors and event times were used to assess the proportional hazards assumption and predicted incidence curves were compared with Kaplan-Meier incidence curves to assess model fit. A generalization of the coefficient of determination, r 2 , was used to evaluate the relative importance of univariate risk factors in predicting outcome risk and to assess the overall predictive strength of multiple risk factor models.
Results
Cranial Neuropathies
The overall actuarial incidence (Kaplan-Meier) of fa-FIG. 1. Left: Computerized tomography scan used for an early radiosurgery treatment plan. A single isocenter was used to encompass the tumor, with the inclusion of normal petrous bone. Five arcs of radiation, with a superoinferior orientation, were used to maximize the dose gradient toward the brainstem, while expanding the irradiated area into the superior temporal lobe and the inferior skull base. The inner line is the 80% isodose line, the middle line is the 40% isodose line (half the prescription dose), and the outer line is the 16% line (20% of the prescription dose). Right: Magnetic resonance image used for a more recent radiosurgery treatment plan. A much more conformal plan is generated by using three separate isocenters. The inner line is the 70% isodose line, the middle line is the 35% isodose line, and the outer line is the 14% isodose line. These two plans reflect the evolution of radiosurgery planning over the past decade toward MR imaging-based highly conformal plans. cial and trigeminal neuropathies at 2 years were 11.8% (95% CI 6.2-17.1%) and 9.5% (95% CI 4.5-14.3%), respectively. The majority of these deficits were transient. Complications diminished markedly, however, as imaging and radiation dose planning as well as dose selection improved ( Fig. 1) . Among the 108 patients treated since January 1994, only five facial and two trigeminal neuropathies occurred. This represents a decrease in the actuarial 2-year incidence of facial neuropathy from 29% for the first 41 patients treated to 5% for the last 108 patients. Similarly, the rate of trigeminal neuropathy has dropped from 29% to 2% for the same patient groups.
Univariate analysis of risk factors indicated that the BSmax was the most informative predictor associated with the incidence of facial, trigeminal, or any neuropathy (r 2 range 0.2-0.44, p Ͻ 0.0001). Delivery of doses greater than 17.5 Gy to the brainstem was associated with a 45-fold greater risk of facial neuropathy relative to cases in which the BSmax was limited to 17.5 Gy or lower (RR 45, 95% CI 14-142, p Ͻ 0.0001). In all five patients who received a dose greater than 17.5 Gy to the brainstem, a facial palsy developed (Fig. 2 left) . Similarly, a BSmax greater than 17.9 Gy conferred a 52-fold greater risk of trigeminal neuropathy (RR 52, 95% CI 15-184, p Ͻ 0.0001; Fig. 2 right) . The RxDose was also significantly predictive for either cranial neuropathy (r 2 range 0.11-0.18). Prescription doses greater than 17.5 Gy incurred 21 times the risk for these complications compared with cases in which RxDoses of 17.5 Gy or less were delivered (RR 21, 95% CI 6-73, p Ͻ 0.0001) (Fig. 3 left) . A more clinically pertinent RxDose cutpoint (Ͼ 12.5 Gy compared with Յ 12.5 Gy) also yielded a significant difference in the risk of cranial neuropathy (Fig. 3 right) . The 2-year incidence of any cranial neuropathy was 2% when prescription doses of 12.5 Gy or less were used, compared with an approximate 24% incidence for doses greater than 12.5 Gy (RR 16, 95% CI 2-116, p Ͻ 0.0003; Fig. 3 right) . The incidence of cranial neuropathy for each prescription dose used in this series is listed in Table 1 . Of course, the BSmax should be less than or equal to the RxDose when conformal planning techniques are used.
Having undergone prior open resection conferred a fivefold greater risk of developing a delayed cranial neuropathy following radiosurgery in this series (RR 4.9, 95% CI 1.9-12.2, p = 0.0002; Fig. 4 ).
Other less important, but statistically significant univariate factors associated with increased risk of facial neuropathy included a pons-petrous tumor diameter greater than 8 mm (RR 5.3, 95% CI 1.2-23, p = 0.014), tumor volume greater than 1.7 cm 3 (RR 4.2, 95% CI 1.2-15, p = 0.016), and patient age younger than 62 years (RR 3.8, 95% CI 1.33-11, p = 0.007; Table 2 ). Absence of MR imagingbased dose planning was a significant risk factor for trigeminal neuropathy (RR 6, 95% CI 1.3-27, p = 0.008), and an estimated length greater than 16 mm for the cranial nerve that was irradiated was a relatively weak predictor of facial neuropathy (RR 7.7, 95% CI 1.02-59, p = 0.019). Use of single-isocenter planning was weakly predictive of an increased incidence of delayed trigeminal neuropathy (RR 3.6, 95% CI 1-13, p = 0.037), but as a rule, neither the number of isocenters used nor the conformality of dosimetry were found to be significant predictors of delayed cranial neuropathy in this series.
Results of Multivariate Analysis
Evaluation of multiple risk factor models showed that
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Risk factors in vestibular schwannoma radiosurgery 443 BSmax, treatment era (pre-1994 compared with 1994 or later), and previous resection were simultaneously informative predictors of cranial neuropathy risk. The RxDose could be substituted for the BSmax with a small loss in predictive strength. Pons-petrous tumor diameter was an additional statistically significant simultaneous predictor of trigeminal neuropathy risk, whereas the distance from the brainstem to the end of the tumor in the petrous bone was an additional marginally significant simultaneous predictor of risk for any cranial neuropathy (Table 3) .
Tumor Control
Among the 133 patients for whom radiological followup data were available, tumor control was achieved in 93% (78 tumors regressed, 45 remained stable, and 10 enlarged). The overall actuarial radiological tumor control rate at 5 years was 87% (95% CI 76-98%; Fig. 5 ). Among the 10 patients in whom tumor growth was observed, six ultimately underwent surgical excision.
The doses that were prescribed varied from 10 to 22.5
Gy in intervals of 2.5 Gy in this series. Analysis of univariate risk factors revealed that a RxDose cutpoint of 10 Gy compared with more than 10 Gy yielded the greatest relative difference in tumor growth risk (RR 2.4, 95% CI 0.6-9.3), although this difference was not statistically significant (p = 0.207). The use of more than two isocenters was associated with a significantly increased risk for tumor growth (RR 6, 95% CI 1.7-21.4, p = 0.002). An irradiated length of nerve (the sum of the pons-petrous tumor diameter and the intracanalicular tumor extension) that is longer than 2.4 cm was also associated with an increased risk of tumor growth (RR 4.8, 95% CI 1.3-17.2, p = 0.008). The isodose, the intracanalicular tumor extension, and the conformality of dosimetry were also statistically significant risk factors (Table 4) , although all of the univariate risk factors found to be significantly associated with tumor growth risk were relatively weak predictors (r 2 range 0.05-0.09). Tumor volume, patient age, and other factors were not predictive of tumor control in this series ( Table 4) . Assessment of multiple risk factor models of tumor growth risk yielded a weakly predictive best model containing a measure of superoinferior tumor diameter and the distance from the brainstem to the end of the tumor in the petrous bone. Tumor growth risk increased in cases in which the superoinferior tumor diameter was 1.5 cm or smaller and also increased when the length of tumor irradiated was greater than 2.4 cm ( Table 5) .
Discussion
Surgical Considerations
The mainstay of treatment for VS has long been resection, which has been significantly refined during the past 20 years. Results have been improved by use of the op- 21, 22, [32] [33] [34] [35] recently published a series of papers in which they documented excellent results after 1000 acoustic schwannoma resections. These authors achieved complete gross anatomical removal of the tumor in 98% of cases and a recurrence rate of only 1% in nonneurofibromatosis Type 2 cases, although the duration of follow up in this study group was not reported. Even in the hands of this master surgeon, however, the surgical morbidity and mortality rates were not negligible. Facial nerve continuity was lost in 7% of patients and, among the remaining 93% with anatomical preservation of the nerve, 45% exhibited new facial deficits. Although many of these patients experienced improved facial function over the 1st postoperative year, 27% of all patients displayed deficits with a House-Brackmann score of 4 or worse, giving them a high likelihood of permanent facial weakness. Other surgical complications included CSF fistula (9%), meningitis (3%), intracranial hemorrhage (2%), lower cranial neuropathies (2%), hemiparesis (1%), tetraparesis (two patients [0.2%]), and death (11 patients [1%]). 33 Among those patients with hearing before surgery, 40% experienced preservation of some hearing postoperatively. In the most recent 200 cases treated by Samii and colleagues, 32 this number improved to 47% hearing preservation; however, the rate of preservation of "useful hearing" (variably defined by different authors) was considerably lower and a function of tumor size and preoperative hearing quality.
Gormley, et al., 7 also recently published their surgical outcomes in 179 patients with VSs. In that series, complete gross anatomical resection was accomplished in 99% of cases with only one recurrence (in the single subtotally resected tumor) over a median follow-up period of 65 months. These authors categorized tumors as small (Ͻ 2 cm), medium (2-3.9 cm), and large (Ն 4 cm) and noted the relationship between tumor size and postoperative cranial nerve function. Surgery resulted in new facial neuropathies (House-Brackman score Ն 3) in 4% of patients with small tumors, 26% with medium-sized tumors, and 62% of those with large tumors. Other reported complications included CSF fistula (15%), meningitis (3%), lower cranial neuropathy (2%), cerebellar/brainstem injury with permanent ataxia (one patient [0.6%]), and death (two patients [1.1%]). Functional hearing preservation was achieved in 48% of cases of small tumors, 25% of those of medium-sized tumors, and in no cases of large tumors.
Other authors have published similar results of surgical treatment for VSs. 3, 25 All these reports have two things in common: 1) they demonstrate the significant strides toward lower rates of surgical morbidity and mortality that have been made in recent years; and 2) they represent optimal results obtained at centers where there is extensive experience in acoustic surgery. It is also worthwhile to note that patients generally report less satisfaction with their outcomes than what might be predicted based on reported surgical outcomes. 40 
Conventional Radiation Therapy
Conventional radiation therapy has not been used extensively for the treatment of VS. Some evidence for efficacy of this modality, however, does exist.
Wallner, et al., 39 reported on 33 patients who underwent subtotal resection of VSs at the University of California in San Francisco. Twenty patients were treated with postop-
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Risk factors in vestibular schwannoma radiosurgery erative external-beam radiotherapy and the remaining 13 patients were observed. Local recurrence occurred in 46% of patients whose tumors were subtotally resected compared with 15% recurrence in patients whose tumors were subtotally resected and who received radiotherapy. Highdose radiation may be preferable given the fact that recurrence occurred in two (67%) of three patients who received less than 45 Gy compared with one (6%) of 17 patients who received more than 45 Gy. The 15-year actuarial local control rate was 41% after subtotal resection alone compared with 94% after subtotal resection plus radiotherapy to doses of more than 45 Gy (p = 0.01) Maire, et al., 19 treated 24 patients harboring 25 VSs by using fractionated external-beam radiotherapy alone at the Hôpital Saint-André in Bordeaux, France, between 1986 and 1992. The mean total dose was 51 Gy and the mean follow-up period was 60 months. The tumor regressed in nine instances (36%), remained stable in 13 (52%), and progressed in three (12%). Two patients died of progressive tumor. The 6-year actuarial rate of local tumor control was 82%.
445
Radiosurgical Procedure
Leksell 15 first used stereotactically guided radiosurgery to treat a VS in 1969. Stereotactic radiosurgery is a logical alternative treatment modality for this tumor for several reasons. The results of in vitro studies have demonstrated that a single radiation dose of 30 Gy devitalizes human Schwann cells. 1 A VS is typically well demarcated from surrounding tissues on neuroimaging studies. The sharp borders of this noninvasive tumor make it a convenient match for the characteristically steep dose gradient produced at the boundary of a radiosurgical target. This allows the surgeon to minimize radiation of normal tissue. Excellent spatial resolution on volumetric gadolinium-enhanced MR images facilitates radiosurgical dose planning. These tumors typically occur in an older population of patients who may be less fit for resection, which is performed while the patient receives a general anesthetic. Finally, as evidenced by the outcomes of surgery detailed earlier, the location of these tumors at the skull base, close to multiple critical neurological structures (that is, cranial nerves and brainstem), leads to appreciable levels of surgical morbidity and rare instances of mortality, even in expert hands. This makes quite attractive the concept of an effective, less invasive, less morbidity-inducing alternative treatment that could be performed in a single session in a patient receiving a local anesthetic. Whether radiosurgery fits this description is currently the subject of ongoing debate. 2, 14, 17, 18, 29, 38 Certainly, the role of radiosurgery is limited by its inability to relieve mass effect expeditiously in patients for * GK = gamma knife; LINAC = linear accelerator; NF2 = neurofibromatosis Type 2; RS = radiosurgery; -= data not given. † Decreased or stable volume. ‡ In this study, dosages of 18 to 20 Gy were used between 1969 and 1988, and 10 to 15 Gy were used between 1989 and 1991.
whom this is necessary. The radiobiology of stereotactic radiosurgery also requires lower, potentially less effective doses for higher target volumes to avoid complications. This limits the use of stereotactic radiosurgery to the treatment of smaller tumors. Despite these limitations, there is a growing body of literature that substantiates the claim that radiosurgery is a safe and effective alternative therapy for VS. The major published series on radiosurgical treatment of VS are summarized in Table 6 . Tumor control has been excellent in all reports, 4, 6, 9, 12, 13, 18, 20, 24, 27, 31, 36, 37 including those with relatively long-term follow-up data. 13, 27 The most notable trend across all series is the marked reduction in cranial nerve morbidity associated with dose reduction. 4, 18, 24, 27, 36 Authors of initial series tended to recommend peripheral doses in the range of 20 Gy. Most groups treating large numbers of VSs now recommend doses in the 12-to 14-Gy range. 4, 11, 24, 26, 27 Other changes in the radiosurgical treatment paradigm have included the nearly routine use of MR imaging rather than computerized tomography scanning for dosimetry planning and the generation of increasingly conformal dose plans using multiple isocenters. Authors of recent series also suggest a high rate of hearing preservation achieved using this approach. 4, 18, 26, 36 
Microsurgery Combined With Radiosurgery
The Pittsburgh and Mayo Clinic gamma knife groups recently published their collective experience with radiosurgery after failed microsurgical treatment of VSs 28 and with microsurgery after failed radiosurgery for VSs. 30 They found that failed radiosurgery requiring subsequent resection was rarely performed in 13 (2.9%) of 452 patients in their series. Although some concern has been expressed regarding the issue, no clear relationship has been demonstrated between the use of radiosurgery and the subsequent ease or difficulty of delayed microsurgery. Because 10 of the 13 patients suffered significant postoperative facial neuropathies, however, it was suggested that a subtotal resection should perhaps be considered for these patients. They also cautioned that, because some patients experience transient enlargement of their tumors following radiosurgery, the need for resection after radiosurgery should be reviewed with the neurosurgeon who performed the radiosurgery and should be delayed until sustained tumor growth is confirmed.
With regard to radiosurgery after failed microsurgery, it was found to be a safe and effective alternative to further microsurgery. Although the rates of facial and trigeminal neuropathy following resection were 55% and 50% for this series, respectively, the rates of new or aggravated facial and trigeminal deficits following postsurgical radiosurgery were 23% and 14%, respectively. Tumor growth control after radiosurgery was achieved in 73 (94%) of 78 tumors in this postsurgical group.
The Current Series
The results of the current analysis suggest that radiation dose to the brainstem is the most significant risk factor for delayed cranial neuropathy after radiosurgery for VS. Tumor margin doses of 17.5 Gy or greater are associated with a high risk of cranial neuropathy, and prescription doses of 12.5 Gy or less carry a very low risk for cranial neuropathy in this series. Interestingly, the relative importance of brainstem dose was confirmed when Meeks, et al., 23 calculated the normal tissue complication probability from brainstem dose-volume histograms generated from this series. The model's fitting parameters were optimized to fit the observed results. This fit suggests that the brainstem is more radiosensitive than parameters in the literature indicate and that there is very little volume effect. In other words, the results of a purely mathematical analysis in which a standard radiobiological model is used also suggest that brainstem dose is a critical factor. Brainstem dose and prescription dose are obviously not independent variables because higher tumor margin doses and closer location to the brainstem result in higher brainstem doses.
It is interesting to note that, in contradistinction to findings in the Pittsburgh series, 5 the use of multiple isocenters and more conformal dose planning did not seem to provide significant protection against cranial neuropathies in this series. Although this may seem surprising, given the well-documented advantages of conformal therapy for most radiosurgical applications, the relative importance of brainstem dose in predicting complications from VS radiosurgery may explain the discrepancy. Although factors such as MR imaging-based dose planning and selection of appropriately small tumors may have contributed to improving outcomes of VS radiosurgery, the overwhelmingly important adjustment that all radiosurgery groups have made appears to be radiation dose reduction. Considering that the BSmax was found to be the most important predictor of postradiosurgical cranial neuropathy, one might postulate that the facial and trigeminal nuclei-or the transition zone from oligodendroglial to Schwann cell myelination of these cranial nerves-are critically sensitive to high-dose irradiation and not the nerves themselves. This suggests that it may be more important to maximize the dose gradient in the direction of the brainstem, minimizing the brainstem dose, than to derive a plan that is perfectly conformal to the margin of the tumor.
Although high doses to the brainstem and tumor margin were overwhelmingly the most important predictors of postradiosurgical cranial neuropathy, other factors were found to be statistically significant. Patients who had previously undergone failed resection of their VSs incurred a fivefold overall increase in the risk of developing a postradiosurgical cranial neuropathy compared with those for whom radiosurgery was the primary treatment modality. Even for these patients, however, the risk of delayed cranial neuropathy is relatively low and has diminished markedly over time. Before January 1994, 15 patients were treated with radiosurgery after attempted resection of their tumors. Of these, cranial neuropathies developed in 10 patients, for a 67% complication rate. Since January 1994, however, delayed facial weakness developed following radiosurgery in only two (6.9%) of the 29 patients who had previously undergone surgery, and no trigeminal palsies have been observed among this subgroup of patients. These more recent complication rates are only slightly higher than those observed for patients who did not undergo surgery previously. It is possible that previous surgery increases the risk of radiosurgery by partially damaging the associated cranial nerves or by decreasing their blood supply and rendering them more susceptible to radiationinduced injury.
The era during which the radiosurgery was performed was an independent predictor of complications in the multivariate analysis. Patients treated at the University of Florida after January 1994 apparently benefited from the increased experience of the radiosurgery team in some intangible way that was not clearly attributable to other variables tested.
As predicted by the Pittsburgh model, 16 the estimated lengths of the fifth and seventh cranial nerves included in the radiosurgical field are statistically significant predictors of delayed cranial neuropathy, but this is a much weaker predictor than radiation dose to the brainstem or prescription dose.
The results of the statistical analysis of tumor control were somewhat less intuitive than those of the complications analysis. The observed trend toward lower rates of tumor control when a dose of 10 Gy was prescribed compared with uniformly excellent tumor control at doses of 12.5 Gy or higher was predictable, but did not reach statistical significance.
Those factors that could be used to predict tumor control seemed to relate to the shape and position of the tumor. The two factors found to be independent predictors of increased risk for tumor growth on multivariate analysis were the pons-petrous tumor diameter plus the length of the intracanalicular tumor extension and the superoinferior tumor diameter.
When we synthesize the results of the complications and tumor control analyses, we arrive at an optimal prescription dose of 12.5 Gy to the margin of a VS. This dose resulted in the best combination of maximum tumor control and minimum complications in this series.
Conclusions
Five points should be made to summarize our conclusions. 1) Cutpoint analysis revealed a trend toward increased risk of tumor growth when peripheral doses less than 12.5 Gy were prescribed. Complex tumors with significant extensions into the petrous bone were associated with a greater risk of tumor growth and thus treatment failure.
2) Cutpoint analysis revealed a statistically significant increase in cranial nerve complications with peripheral doses of 15 Gy or higher. Other statistically significant predictors of cranial neuropathy in a multivariate analysis were maximum dose delivered to the brainstem and prior resection.
3) This analysis did not demonstrate a statistically significant value to conformal, multiple isocenter planning in preventing cranial neuropathy. Overall findings suggest that decreasing radiation doses, rather than increasing the conformality of treatment planning, has played the most important role in improving the results of radiosurgery for VS.
4) This analysis did show a correlation between the length of the cranial nerve irradiated and the incidence of cranial neuropathy, as had been previously reported; however, this was a much weaker predictor of delayed cranial neuropathy than maximum radiation dose to the brainstem. This suggests that the critical site of injury after radiosurgery may be located at the cranial nerve nucleus or the transition zone rather than along the course of the nerve.
5) Radiosurgery, when performed using modern imaging and dose-planning methodology, is a safe and effective treatment for small VSs. With careful dose planning and delivery, the incidence of delayed cranial neuropathy can be reduced to below those reported in the best modern surgical series. Tumor control rivals the best surgical outcomes and the morbidity associated with open resection is avoided.
